A rare case of septic shock due to Neisseria meningitidis serogroup B infection despite prior vaccination in a young adult with paroxysmal nocturnal haemoglobinuria receiving eculizumab.

[1]  S. Ladhani,et al.  Meningococcal B Vaccine Failure With a Penicillin-Resistant Strain in a Young Adult on Long-Term Eculizumab , 2017, Pediatrics.

[2]  D. Granoff,et al.  Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults. , 2017, Blood.

[3]  J. Macneil,et al.  High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine , 2017, MMWR. Morbidity and mortality weekly report.

[4]  S. Felix,et al.  Extracorporeal cytokine elimination as rescue therapy in refractory septic shock: a prospective single-center study , 2017, Journal of Artificial Organs.

[5]  C. Picard,et al.  Strains Responsible for Invasive Meningococcal Disease in Patients With Terminal Complement Pathway Deficiencies , 2017, The Journal of infectious diseases.

[6]  S. H. Real,et al.  Meningococcemia in vaccinated patient under treatment with eculizumab. , 2017 .

[7]  Silvia Vega Castaño,et al.  Infección meningocócica en paciente vacunado y en tratamiento con eculizumab , 2017 .

[8]  U. Dührsen,et al.  Serologic response to meningococcal vaccination in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with the terminal complement inhibitor eculizumab , 2017, Annals of Hematology.

[9]  H. Pfister,et al.  [Bacterial meningitis in adults in emergency and rescue services]. , 2016, Medizinische Klinik, Intensivmedizin und Notfallmedizin.

[10]  M. Klein,et al.  Bakterielle Meningitis bei Erwachsenen im Notfall- und Rettungswesen , 2016, Medizinische Klinik - Intensivmedizin und Notfallmedizin.

[11]  J. Montoya,et al.  Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis , 2016, Current opinion in infectious diseases.

[12]  Susan A. Lippold,et al.  Notes from the Field: Meningococcal Disease in an International Traveler on Eculizumab Therapy - United States, 2015. , 2016, MMWR. Morbidity and mortality weekly report.

[13]  M. Pizza,et al.  Effectiveness of Meningococcal B Vaccine against Endemic Hypervirulent Neisseria meningitidis W Strain, England , 2016, Emerging infectious diseases.

[14]  J. Schubert,et al.  Update on paroxysmal nocturnal haemoglobinuria: on the long way to understand the principles of the disease , 2015, European journal of haematology.

[15]  P. Heeger,et al.  Molecules Great and Small: The Complement System. , 2015, Clinical journal of the American Society of Nephrology : CJASN.

[16]  C. Gerloff,et al.  Clinical Features of Critically Ill Patients With Shiga Toxin–Induced Hemolytic Uremic Syndrome , 2013, Critical care medicine.

[17]  M. Valenzuela,et al.  Persistence of antibodies in adolescents 18−24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine , 2013, Human vaccines & immunotherapeutics.

[18]  R. Rappuoli,et al.  Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. , 2013, The Lancet. Infectious diseases.

[19]  G. Rijkers,et al.  Meningococcal Sepsis Complicating Eculizumab Treatment Despite Prior Vaccination , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[20]  M. Pizza,et al.  Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa? , 2013, Vaccine.

[21]  W. Gregory,et al.  Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. , 2010, Blood.

[22]  B. C. Hellerud,et al.  Critical Roles of Complement and Antibodies in Host Defense Mechanisms against Neisseria meningitidis as Revealed by Human Complement Genetic Deficiencies , 2009, Infection and Immunity.

[23]  R. Brodsky.  How I treat paroxysmal nocturnal hemoglobinuria. , 2009, Blood.

[24]  Lee H Harrison,et al.  Global epidemiology of meningococcal disease. , 2009, Vaccine.

[25]  Lihua Wu,et al.  Ginseng stem-leaf saponins (GSLS) and mineral oil act synergistically to enhance the immune responses to vaccination against foot-and-mouth disease in mice. , 2009, Vaccine.

[26]  A. Nierhaus,et al.  Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock * , 2007, Critical care medicine.

[27]  I. Kluijt,et al.  A family with complement factor D deficiency. , 2001, The Journal of clinical investigation.

[28]  P. Densen,et al.  Infectious diseases associated with complement deficiencies , 1991, Clinical Microbiology Reviews.